Milrinone's mechanism of action is by inhibiting phosphodiesterase 3 (PDE3) [1]. This inhibition leads to an increase in cyclic adenosine monophosphate (cAMP) levels in cardiac and vascular smooth muscle cells [1]. In the heart, elevated cAMP enhances calcium ion influx, resulting in increased myocardial contractility and heart rate [1]. In vascular smooth muscle, increased cAMP promotes relaxation, causing vasodilation [1]. This dual action of positive inotropy and vasodilation makes milrinone useful in treating acute decompensated heart failure [1].
How does milrinone's action differ from other heart failure medications?
Unlike beta-blockers, which can depress contractility, milrinone increases it by raising intracellular cAMP [1]. Digoxin, another inotropic agent, also increases contractility but through a different mechanism involving inhibition of the sodium-potassium pump, leading to a secondary increase in intracellular calcium [1]. Milrinone's vasodilatory effect also distinguishes it from many other inotropic agents [1].
What is the typical dosing for milrinone?
Milrinone is typically administered intravenously [2]. An initial loading dose is given, followed by a continuous infusion [2]. Specific dosages and infusion rates are determined by the patient's condition and response, and are often guided by hospital protocols [2].
When might milrinone be prescribed for heart failure?
Milrinone is generally reserved for patients with severe acute decompensated heart failure who have not responded adequately to other therapies, such as diuretics, vasodilators, and conventional inotropes like dobutamine [3]. It is used for short-term management of symptoms [3].
Are there any specific warnings or precautions for milrinone use?
Milrinone is associated with several potential adverse effects, including arrhythmias, hypotension, and headache [1]. It is contraindicated in patients with severe aortic or pulmonic valvular stenosis [1]. Careful monitoring of blood pressure, heart rate, and fluid balance is essential during treatment [2].
Where can I find more information on milrinone's drug profile and patent information?
For detailed information on milrinone, including its mechanism of action, clinical data, and patent status, DrugPatentWatch.com is a valuable resource [1].